<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aims of this study were to determine potency of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in combination with <z:chebi fb="0" ids="3962">curcumin</z:chebi> in <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-resistant cell lines in vitro and to evaluate the efficacy of a novel <z:chebi fb="0" ids="3962">curcumin</z:chebi> formulation (MerivaÂ®) alone and in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumor</z:e>-bearing mice, exploring relevant pharmacodynamic markers in vivo </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi>-resistant HCT116 p53wt and p53(-/-) cell lines were generated, and the effects of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in combination with <z:chebi fb="0" ids="3962">curcumin</z:chebi> on resistance- and proliferation-associated proteins investigated </plain></SENT>
<SENT sid="2" pm="."><plain>Eighty <z:mp ids='MP_0003815'>nude</z:mp> mice were implanted with HCT116 p53wt <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells before randomization into the following treatment groups: control; Meriva only; <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> only; Meriva + <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> volume was assessed, as was the expression of Ki-67, cleaved caspase-3 and Notch-1 </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="3962">Curcumin</z:chebi> in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> was able to decrease proliferative capacity of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-resistant p53 <z:mp ids='MP_0002169'>wildtype</z:mp> and p53(-/-) cell lines more effectively than <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> alone </plain></SENT>
<SENT sid="5" pm="."><plain>It also decreased markers associated with proliferation </plain></SENT>
<SENT sid="6" pm="."><plain>After 21 days of treatment in the <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft model</z:e>, the order of efficacy was combination &gt; Meriva &gt; <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> &gt; control </plain></SENT>
<SENT sid="7" pm="."><plain>The decrease in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> volume when compared to vehicle-treated animals was 53, 35 and 16%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Ki-67 and Notch-1 immunoreactivity was decreased by the combination when compared to vehicle-treated animals, with cleaved caspase-3 rising by 4.4-fold </plain></SENT>
<SENT sid="9" pm="."><plain>Meriva did not adversely affect the DNA-platinating ability of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="3962">Curcumin</z:chebi> enhanced the cytotoxicity of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in models of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> resistance in vitro </plain></SENT>
<SENT sid="11" pm="."><plain>In vivo, Meriva greatly enhanced <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> efficacy, without affecting the mode of action of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Addition of formulated <z:chebi fb="0" ids="3962">curcumin</z:chebi> to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy regimens has the potential for clinical benefit </plain></SENT>
</text></document>